BioCentury
ARTICLE | Clinical News

Botox onabotulinumtoxinA regulatory update

February 20, 2012 8:00 AM UTC

Allergan disclosed in its 4Q11 earnings that Health Canada approved Botox onabotulinumtoxinA as a prophylactic to treat chronic migraine in adults. GlaxoSmithKline has rights from Allergan to develop ...